Ascendis Pharma AS
(NAS:ASND)
$
137.5
-2.81 (-2%)
Market Cap: 8.39 Bil
Enterprise Value: 8.62 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 71/100 Ascendis Pharma A/S at Citi BioPharma Conference Transcript
Sep 07, 2022 / 07:30PM GMT
Release Date Price:
$90.95
(+3.22%)
David Neil Lebowitz
Citigroup Inc., Research Division - Research Analyst
Thank you once again for attending the Citi 17th Annual Biopharma Conference. I'm happy to have in our next session from Ascendis Pharma, we have Scott Smith and Tim Lee. I guess if we could start off, could you just give a top-level overview of Ascendis and the TransCon platform.
Timothy J. Lee;S;Senior Director of IR
Ascendis Pharma A
/-
Sure. Before we start, if I can just give the FLS from disclaimer standpoint. We may make forward-looking comments through the presentation today. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in our SEC filings.
And with that, Scott, why don't you take it away?
Scott T. Smith;S;CFO
Ascendis Pharma A;Senior VP & Member of Executive Board
/- -
Thanks, Tim. Thanks, Dave, for the invitation here in the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot